Education
About Us
Working with TipRanks
Follow Us
CARsgen Therapeutics Holdings Ltd. (HK:2171)
:2171
2171 Stock Chart & Stats
HK$14.89
HK$0.27(2.96%)
At close: 4:00 PM EST
HK$14.89
HK$0.27(2.96%)
Day’s Range― - ―
52-Week RangeHK$9.90 - HK$25.60
Previous CloseN/A
Volume4.65M
Average Volume (3M)1.98M
Market Cap
HK$9.32B
Enterprise ValueHK$6.71B
Total Cash (Recent Filing)HK$1.12B
Total Debt (Recent Filing)HK$61.20M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 25, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding578,130,500
10 Day Avg. Volume1,760,508
30 Day Avg. Volume1,977,652
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)9.44
Price to Sales (P/S)60.15
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.08Price Target Upside95.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.47
Revenue Forecast (FY)HK$1.10B
Bulls Say, Bears Say
Bulls Say
Strong 2025 Revenue Growth And Positive Gross ProfitMeaningful top-line growth with positive gross margin indicates the company is moving from pure R&D spend toward commercial traction or higher-yield activity. That structural shift improves long-term scalability and the potential to leverage fixed R&D and manufacturing investments into improved operating leverage if growth persists.
Reduced Leverage With Sizeable Asset/equity BaseA marked reduction in debt and substantial asset/equity base improves financial flexibility and lowers near-term interest and refinancing risk. This structural improvement strengthens the company’s ability to fund continued clinical programs and capex from a healthier balance sheet versus prior higher-leverage years.
Vertical Integration In CAR‑T R&D And ManufacturingOwning research, process development and manufacturing creates a durable competitive advantage in cell therapy: better control of quality, cost and timelines. Vertical capabilities reduce outsourcing risk, support faster iteration of candidates, and can improve gross margins as scale and platform learning accrue.
Bears Say
Deep, Persistent Negative Operating Cash FlowSustained negative operating cash flow is a structural constraint: it requires repeated external funding or asset sales to sustain R&D and operations. Continued cash burn undermines runway, risks dilution or higher-cost financing, and limits the company’s ability to invest opportunistically or respond to setbacks without capital injections.
Large Ongoing Operating Losses Despite Revenue GainsPersistent operating deficits show the business is not yet profitable at scale; even with better revenues, high operating expenses (R&D, SG&A, manufacturing ramp) keep margins negative. Structural losses raise questions about the time and capital required to reach sustainable profitability and returns for investors.
Erosion Of Equity Over Multiple YearsA multi-year decline in equity indicates cumulative losses have materially weakened the balance sheet buffer. That trend reduces financial resilience, may constrain financing options, and increases vulnerability to adverse clinical or market developments unless profitable operations or fresh capital reverse the erosion.
CARsgen Therapeutics Holdings Ltd. News
2171 FAQ
What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$9.90 and its highest was HK$25.60 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$9.32B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 160 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Mar 06, 2026. The company reported -HK$0.045 earnings per share for the quarter, beating the consensus estimate of -HK$0.158 by HK$0.113.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Undervalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.21.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 578,130,500 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.045 in its last earnings report, beating expectations of -HK$0.158. Following the earnings report the stock price went down -9.114%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CARsgen Therapeutics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
330.42%
12-Months-Change
Fundamentals
Return on Equity
-11.84%
Trailing 12-Months
Asset Growth
-19.17%
Trailing 12-Months
Company Description
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
2171 Stock 12 Month Forecast
Average Price Target
HK$29.08
▲(95.30% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
Everest Medicines Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Options Prices
Currently, No data available
---